These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18020501)

  • 21. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
    Farrar WL; Harel-Bellan A; Ferris DK
    Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Deep lung--cellular reaction to HIV].
    Tavares Marques MA; Alves V; Duque V; Botelho MF
    Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120.
    Dianzani U; Bragardo M; Buonfiglio D; Redoglia V; Funaro A; Portoles P; Rojo J; Malavasi F; Pileri A
    Eur J Immunol; 1995 May; 25(5):1306-11. PubMed ID: 7539755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant glycoprotein 120 of human immunodeficiency virus is a potent interferon inducer.
    Capobianchi MR; Ankel H; Ameglio F; Paganelli R; Pizzoli PM; Dianzani F
    AIDS Res Hum Retroviruses; 1992 May; 8(5):575-9. PubMed ID: 1381203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T; Boyd MR
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
    Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
    J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
    Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
    J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity.
    Richard J; Veillette M; Ding S; Zoubchenok D; Alsahafi N; Coutu M; Brassard N; Park J; Courter JR; Melillo B; Smith AB; Shaw GM; Hahn BH; Sodroski J; Kaufmann DE; Finzi A
    EBioMedicine; 2016 Jan; 3():122-134. PubMed ID: 26870823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells.
    Crowe SM; Mills J; Kirihara J; Boothman J; Marshall JA; McGrath MS
    AIDS Res Hum Retroviruses; 1990 Aug; 6(8):1031-7. PubMed ID: 1977427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
    Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
    J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
    Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
    AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
    Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.
    Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P
    J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.
    Hou W; Fang C; Liu J; Yu H; Qi J; Zhang Z; Yuan R; Xiong D; Gao S; Adam Yuan Y; Li S; Gu Y; Xia N
    Antiviral Res; 2015 Oct; 122():101-11. PubMed ID: 26259811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.
    Allaway GP; Davis-Bruno KL; Beaudry GA; Garcia EB; Wong EL; Ryder AM; Hasel KW; Gauduin MC; Koup RA; McDougal JS
    AIDS Res Hum Retroviruses; 1995 May; 11(5):533-9. PubMed ID: 7576908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
    Traunecker A; Lüke W; Karjalainen K
    Nature; 1988 Jan; 331(6151):84-6. PubMed ID: 2829024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.